Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Dr Elena Castro (Hospital Universitario 12 de Octubre, Madrid, Spain), Dr Pasquale Rescigno (Newcastle University, Newcastle, UK), Prof Gert Attard (University College London Cancer Institute, UK) and Dr Axel Heidenreich (University Hospital Cologne, Cologne,Germany) discuss best practice in precision medicine for prostate cancer.
The panel explores how personalised medicine is transforming prostate cancer care.
They talk about the latest clinical trial data on targeted agents, PARP inhibitors, AR pathway inhibitors, and immunotherapy.
They also cover strategies for patient-tailored treatment selection in mHSPC and biochemically recurrent disease, the critical role of early and timely testing, including genomic and molecular diagnostics for treatment guidance and designing care pathways that prioritise patient outcomes, quality of life, and long-term disease control.
| EMBARK: Overall survival with enzalutamide in biochemically recurrent prostate cancer | |
| Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303) | |
| A phase III study of capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281 | |
| Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition) | |
| 3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial | |
| First interim efficacy analysis of the phase I/II PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC) | |
| Translational analyses of T cell phenotypes and their association with clinical efficacy in the first-in-human (FIH) trial of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC) |
